

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
Steffen Goletz et al.)	Group Art Unit: 1633
)	
Application No.: 10/568,098)	Examiner: Leavitt, Maria
)	
Filed: June 20, 2006)	Confirmation No.: 8158
)	
For: TUMOR CELL LINES AND USES)	
THEREOF)	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants' Interview Summary

Applicants wish to thank Examiner Leavitt for her availability and courtesy during an Examiner interview on October 23, 2009. Applicants discussed the outstanding rejections under 35 U.S.C. § 112, first paragraph (enablement; claims 20 and 22), 35 U.S.C. § 102(b) (claim 1), and 35 U.S.C. § 103(a) (claims 1, 5, 6, 11, 12, and 24). The Examiner has agreed to allow the application with an Examiner's Amendment, which cancels claims 7, 9, 10, 20, and 22 and amends claims 1, 3, 11, and 24. The Examiner indicated that a Notice of Allowance would issue shortly. All amendments are made without prejudice and Applicants reserve the right to pursue any cancelled subject matter in one or more continuing applications.

For clarity, Applicants briefly summarize the amendments to claims 1, 3, 11 and 24 discussed with the Examiner. Claims 1, 3 (part c), and 11 (part a) would be

amended to state that the cells expressing TF, MUC1 and glycoporphin, *synthesize* and express TF, MUC1 and glycoporphin, *wherein the TF is exposed*. Claim 11 would also be amended to delete parts "b," "c," and "d." Claim 24 would be amended to write out the term "tumor-associated MUC1."

The Examiner is encouraged to call the undersigned with any questions or comments. Applicants do not believe any fees are required to enter this paper. However, in the event of an error, the Commissioner is authorized to charge any required fees to deposit account number 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: October 23, 2009

By: 

Laurence A. Shumway, Ph.D.
Reg. No. 61,169
617.452.1689